EGFR and non-small cell lung carcinoma: In a randomized controlled trial of erlotinib versus gefitinib in advanced NSCLC patients harboring EGFR exon 19 or 21 mutations, patients were enrolled regardless of their line of treatment in order to determine whether erlotinib is superior to gefitinib in terms of response and survival.